array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(55) "Preliminary rendering off proposed Regeneron expansion."
["snippet_en"]=>
string(55) "Preliminary rendering off proposed Regeneron expansion."
["url"]=>
string(176) "https://westfaironline.com/combined/westchester-ida-supports-2-2b-worth-of-projects-in-2023-4b-over-two-years/attachment/preliminary-rendering-off-proposed-regeneron-expansion/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c8a04296-b0c9-4f28-b69d-4411ac95e4bf"
["source"]=>
string(18) "westfaironline.com"
["publication_date"]=>
string(10) "2024-02-11"
["categories"]=>
array(1) {
[0]=>
string(18) "Expansion & Growth"
}
}
[1]=>
array(7) {
["title_en"]=>
string(58) "Shoreham-Wading River High School opens new fitness center"
["snippet_en"]=>
string(232) "Abraham Lincoln’s famous quote, “The best way to predict the future is to create it,” now embellishes the wall of Shoreham-Wading River High School’s new state-of-the-art Health and Wellness Center, which is officially open."
["url"]=>
string(118) "https://riverheadnewsreview.timesreview.com/2023/12/118493/shoreham-wading-river-high-school-opens-new-fitness-center/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/86450a69-2f5b-4bd7-925b-102a30c82748"
["source"]=>
string(15) "timesreview.com"
["publication_date"]=>
string(10) "2023-12-20"
["categories"]=>
array(4) {
[0]=>
string(17) "Academic Research"
[1]=>
string(7) "Opening"
[2]=>
string(11) "Competition"
[3]=>
string(18) "Expansion & Growth"
}
}
[2]=>
array(7) {
["title_en"]=>
string(58) "EC expands use of Evkeeza for pediatric patients with HoFH"
["snippet_en"]=>
string(58) "EC expands use of Evkeeza for pediatric patients with HoFH"
["url"]=>
string(98) "https://www.thepharmaletter.com/article/ec-expands-use-of-evkeeza-for-pediatric-patients-with-hofh"
["image_url"]=>
NULL
["source"]=>
string(19) "thepharmaletter.com"
["publication_date"]=>
string(10) "2023-12-19"
["categories"]=>
array(1) {
[0]=>
string(18) "Expansion & Growth"
}
}
[3]=>
array(7) {
["title_en"]=>
string(67) "Albany County IDA considers proposed Regeneron expansion in Menands"
["snippet_en"]=>
string(202) "ALBANY, N.Y. — The Albany County Industrial Development Agency (IDA) is currently considering an application and scheduled a public hearing for a proposed expansion project by Regeneron Pharmaceuti..."
["url"]=>
string(106) "https://www.troyrecord.com/2023/11/07/albany-county-ida-considers-proposed-regeneron-expansion-in-menands/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3e7cefe0-242c-4549-99e1-bb4ee42629a4"
["source"]=>
string(14) "troyrecord.com"
["publication_date"]=>
string(10) "2023-11-06"
["categories"]=>
array(2) {
[0]=>
string(19) "Under Investigation"
[1]=>
string(18) "Expansion & Growth"
}
}
[4]=>
array(7) {
["title_en"]=>
string(43) "Regeneron seeks expansion into Menands site"
["snippet_en"]=>
string(85) "18-acre property on Broadway being considered by pharmaceutical firm; hearing planned"
["url"]=>
string(95) "https://www.timesunion.com/business/article/regeneron-seeks-expansion-menands-site-18463227.php"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9fd9fc2d-5256-4b0e-bc29-5be0cfb0303f"
["source"]=>
string(14) "timesunion.com"
["publication_date"]=>
string(10) "2023-11-01"
["categories"]=>
array(2) {
[0]=>
string(25) "Business Model Resilience"
[1]=>
string(18) "Expansion & Growth"
}
}
[5]=>
array(7) {
["title_en"]=>
string(186) "Recombinant Therapeutic Protein Market To Witness the Highest Growth Globally in Coming Years 2023-2030 | Boehringer Ingelheim, Regeneron Pharmaceuticals, Eli Liily, Bristol-Myers Squibb"
["snippet_en"]=>
string(96) "The global Recombinant Therapeutic Protein Market has witnessed significant recent developments,"
["url"]=>
string(233) "https://www.digitaljournal.com/pr/news/cdn-newswire/recombinant-therapeutic-protein-market-to-witness-the-highest-growth-globally-in-coming-years-2023-2030-boehringer-ingelheim-regeneron-pharmaceuticals-eli-liily-bristol-myers-squibb"
["image_url"]=>
NULL
["source"]=>
string(18) "digitaljournal.com"
["publication_date"]=>
string(10) "2023-10-05"
["categories"]=>
array(3) {
[0]=>
string(11) "Competition"
[1]=>
string(15) "Market Movement"
[2]=>
string(18) "Expansion & Growth"
}
}
[6]=>
array(7) {
["title_en"]=>
string(84) "Intellia, Regeneron to take CRISPR collaboration outside the liver with revised deal"
["snippet_en"]=>
string(298) "Intellia Therapeutics and Regeneron Pharmaceuticals hope to take their CRISPR partnership outside the liver with an expansion on their existing work that yielded first-in-human gene editing data in| Intellia and Regeneron hope to take their CRISPR partnership outside the liver with an expansion on"
["url"]=>
string(118) "https://www.fiercebiotech.com/biotech/intellia-and-regeneron-want-take-crispr-collaboration-outside-liver-revised-deal"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dc9b2577-ef23-4463-b43a-67228df91fcb"
["source"]=>
string(17) "fiercebiotech.com"
["publication_date"]=>
string(10) "2023-10-03"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(18) "Expansion & Growth"
}
}
[7]=>
array(7) {
["title_en"]=>
string(78) "AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron"
["snippet_en"]=>
string(69) "Subscribe now to read the latest news in your city and across Canada."
["url"]=>
string(136) "https://ottawasun.com/pmn/business-wire-news-releases-pmn/abcellera-expands-multi-target-antibody-discovery-collaboration-with-regeneron"
["image_url"]=>
NULL
["source"]=>
string(13) "ottawasun.com"
["publication_date"]=>
string(10) "2023-09-20"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(18) "Expansion & Growth"
}
}
[8]=>
array(7) {
["title_en"]=>
string(74) "Regeneron partners with US Government to develop Covid-19 antibody vaccine"
["snippet_en"]=>
string(131) "The programme is part of US BARDA’s ‘Project NextGen’ to develop countermeasures against Covid-19 current and future strains."
["url"]=>
string(122) "https://www.pharmaceutical-technology.com/news/regeneron-partners-with-us-government-to-develop-covid-19-antibody-vaccine/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ffd3daa8-03da-426a-8b37-3e3466ff3c2b"
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-08-23"
["categories"]=>
array(5) {
[0]=>
string(14) "Product Launch"
[1]=>
string(18) "Expansion & Growth"
[2]=>
string(11) "Nationalism"
[3]=>
string(13) "Collaboration"
[4]=>
string(8) "Epidemic"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Abraham Lincoln’s famous quote, “The best way to predict the future is to create it,” now embellishes the wall of Shoreham-Wading River High School’s new state-of-the-art Health and Wellness Center, which is officially open.
ALBANY, N.Y. — The Albany County Industrial Development Agency (IDA) is currently considering an application and scheduled a public hearing for a proposed expansion project by Regeneron Pharmaceuti...
Intellia Therapeutics and Regeneron Pharmaceuticals hope to take their CRISPR partnership outside the liver with an expansion on their existing work that yielded first-in-human gene editing data in| Intellia and Regeneron hope to take their CRISPR partnership outside the liver with an expansion on
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
